Completed PHASE1 INTERVENTIONAL 1-arm NCT00328562

ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer

A Phase I Study of ZD1839 (Iressa) and Hypofractionated Thoracic Radiotherapy With Stereotactic Body Frame Immobilization for Patients With Advanced Non-Small Cell Lung Cancer

Sponsor: AstraZeneca

Conditions Non-Small Cell Lung Carcinoma (NSCLC)

Interventions Thoracic Radiotherapy ZD1839 (Iressa)

Updated 8 times since 2017 Last updated: May 1, 2025 Started: Dec 31, 2003 Primary completion: Apr 30, 2008 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00328562, this PHASE1 trial focuses on Non-Small Cell Lung Carcinoma (NSCLC) and remains completed. Sponsored by AstraZeneca, it has been updated 8 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Feb 2026 — Present [monthly]

Completed PHASE1
Jun 2025 — Feb 2026 [monthly]

Completed PHASE1
Sep 2024 — Jun 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AstraZeneca
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Data source: Thomas Jefferson University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Philadelphia, United States